AIQ Solutions

AIQ Solutions, founded in 2018 and based in Cambridge, Massachusetts, is a private diagnostics company operating at the intersection of AI and oncology. The company has developed and received FDA 510(k) clearance for TRAQinform IQ, a cloud-based software platform that analyzes serial PET/CT scans to measure intra-patient tumor response heterogeneity, providing prognostic insights superior to standard methods like RECIST. By enabling more precise therapy adjustments in late-stage cancer care, AIQ targets a significant unmet need in the oncology workflow, supported by recent clinical data and the establishment of a Category III CPT code for its service.

TRAQinform IQ: A cloud-based, FDA-cleared software medical device that uses AI to perform quantitative, lesion-by-lesion analysis of serial PET/CT scans. It calculates SUVhetero, a proprietary metric of intra-patient tumor response heterogeneity, to provide prognostic insights beyond standard RECIST/PERCIST measurements.

AIQ competes in the broad medical imaging AI market but is specialized in quantitative, longitudinal analysis of tumor heterogeneity. Direct competitors may include other companies offering advanced oncology image analytics (e.g., for clinical trials). Its primary competition is the entrenched standard of care (RECIST/PERCIST) and the manual, qualitative assessment performed by radiologists and oncologists.